Kimia Biosciences Ltd (BSE: 530313) is a New Delhi, Delhi-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹151 Cr, it ranks #2,886 by market cap among the 6,197 Indian listed companies on FinBizNet, and #59 of 86 in Medicinal Chemicals and Botanical Products. At ₹32.50 (as of 16 Nov 2026), the share price is 24.9% below its 52-week high of ₹43.28 and 40.1% above its 52-week low of ₹23.20. The share price is up 4.6% over one year and up 12.9% over three months.
| Current Price | ₹32.50 |
|---|---|
| Market Cap | ₹151 Cr |
| BSE Code | 530313 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 20.4 |
| Return on Equity | 53.70% |
| Return on Assets | 7.26% |
| 52-Week Range | ₹23.20 – ₹43.28 |
| 1-Year Price Change | +4.6% |
| 3-Month Price Change | +12.9% |
| Beta (1Y) | 1.44 |
| Headquarters | New Delhi, Delhi |
| Website | www.kimiabiosciences.com |
Delivery averaged 90.8% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Kimia Biosciences Limited manufactures and sells active pharmaceutical ingredients (APIs) in India. The company offers and develops APIs in the categories, including gastrointestinal agent, anti-coagulant, anti-hypertensive, lipid lowering agents, vitamin, anti-histamine, anti-convulsant, central stimulant, anti-diabetic, and anti-bacterial, as well as anti-psychotic, anti-fungal, urologicals, anti-inflammatory, prokinetic agent, cholelithiasis agent, anti-asthmatic, anti-depressant, anti-acne, decongestant, and anti-virals. It exports its products. Kimia Biosciences Limited was formerly known as Laurel Organics Ltd and changed its name to Kimia Biosciences Limited January 2019. The company was incorporated in 1993 and is based in New Delhi, India.
1. Pharmaceuticals-This segment provides contract manufacturing services for latest (R&D based) and generic (regular) bulk drug intermediates for pharmaceutical companies in India.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Kimia Biosciences Ltd | ₹151 Cr | 20.4 | 53.70% | — | +4.6% |
Listed by market capitalisation. Ratios are shown for context only.
Kimia Biosciences Ltd is trading at ₹32.50, with a market capitalisation of ₹151 Cr.
Kimia Biosciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Kimia Biosciences Ltd has a P/E of 20.4 and a return on equity of 53.70%.
Kimia Biosciences Ltd is listed on the BSE under the scrip code 530313.
Kimia Biosciences Ltd's share price is up 4.6% over one year and up 12.9% over three months. Its 52-week range is ₹23.20 to ₹43.28.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.